Opinion
Published on 09 Dec 2022
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension
in Cardiovascular Endocrinology
- 17,867 views
- 18 citations
Opinion
Published on 09 Dec 2022
in Cardiovascular Endocrinology
Original Research
Published on 09 Dec 2022
in Obesity
Original Research
Published on 09 Dec 2022
in Cancer Endocrinology
Editorial
Published on 09 Dec 2022
in Reproduction
Original Research
Published on 09 Dec 2022
in Obesity
Systematic Review
Published on 09 Dec 2022
in Obesity
Original Research
Published on 09 Dec 2022
in Obesity
Original Research
Published on 09 Dec 2022
in Pediatric Endocrinology
Original Research
Published on 09 Dec 2022
in Clinical Diabetes
Original Research
Published on 09 Dec 2022
in Obesity
Original Research
Published on 09 Dec 2022
in Clinical Diabetes
Review
Published on 09 Dec 2022
in Molecular and Structural Endocrinology
Review
Published on 09 Dec 2022
in Translational and Clinical Endocrinology
Original Research
Published on 09 Dec 2022
in Reproduction
Original Research
Published on 09 Dec 2022
in Thyroid Endocrinology
Mini Review
Published on 09 Dec 2022
in Diabetes: Molecular Mechanisms